Invectys Competitors and Similar CompaniesClear all
Invectys's competitors and similar companies include Ascentage Pharma, Achilles Therapeutics, Chugai Pharmaceutical and Epizyme.
 Invectys Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. |  Ascentage Pharma Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies. |  Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. |  Chugai Pharmaceutical Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases. |  Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors. | |
Founding Date | Founding Date 2010 | Founding Date 2017 | Founding Date 2016 | Founding Date 1925 | Founding Date 2007 |
Type | Type Private | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Paris, FR HQ Houston, US Houston, US | Locations Suzhou, CN HQ Guangzhou Shi, CN Suzhou Shi, CN Taizhou, CN Rockville, US | Locations London, GB HQ Stevenage, GB | Locations Chuo City, JP HQ Guangzhou Shi, CN Taizhou, CN Puteaux, FR Frankfurt Am Main, DE Singapore, SG see more | Locations Cambridge, US HQ |
Employees | Employees 18 | Employees 567 | Employees 695% decrease | Employees 7,778 | Employees 20364% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 78.7 b | Valuation ($) 250.8 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥574.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) ¥1.3t (FY, 2025) | Revenue (est.) $37.4m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods ¥48.9m (FY, 2025) | Cost of goods N/A | Cost of goods ¥363.7b (FY, 2025) | Cost of goods $10.5m (FY, 2021) |
Gross profit | Gross profit N/A | Gross profit ¥546.6m (FY, 2025) | Gross profit N/A | Gross profit ¥903.5b (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income (¥1.2b) (FY, 2025) | Net income ($69.7m) (FY, 2023) | Net income ¥434b (FY, 2025) | Net income ($251.1m) (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised $ 4.7m | Total funding raised $ 237.5m | Total funding raised $ 138.1m | Total funding raised N/A | Total funding raised $ 51.5m |
For sources of this data, please see the company profile
View Company Profiles
Ascentage Pharma
HQ
Suzhou, CN
Employees
567
Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies.
View companyAchilles Therapeutics
HQ
London, GB
Employees
69↓ 5% decrease
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View companyChugai Pharmaceutical
HQ
Chuo City, JP
Employees
7,778
Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases.
View companyEpizyme
HQ
Cambridge, US
Employees
203
Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.
View company